# Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

> **NCT03397121** · PHASE3 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 482 (actual)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia
- Elevated Cholesterol

## Interventions

- **DRUG:** Inclisiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03397121
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2019-08-27
- **Final completion:** 2019-09-17
- **Target enrollment:** 482 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03397121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03397121, "Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03397121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*